|
May 6
|
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
|
|
Mar 26
|
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
|
|
Mar 23
|
Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
|
|
Mar 22
|
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
|
|
Mar 18
|
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
|
|
Feb 9
|
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
|
|
Aug 7
|
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023
|
|
Aug 3
|
Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)
|